Home » Stocks » Immatics

Immatics N.V. (IMTX)

Stock Price: $9.95 USD -0.42 (-4.05%)
Updated Aug 14, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 625.94M
Revenue (ttm) n/a
Net Income (ttm) -35.20M
Shares Out 62.91M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 14, 2020
Last Price $9.95
Previous Close $10.37
Change ($) -0.42
Change (%) -4.05%
Day's Open 10.10
Day's Range 9.74 - 10.32
Day's Volume 679,850
52-Week Range 9.51 - 17.25

More Stats

Market Cap 625.94M
Enterprise Value 625.30M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 62.91M
Float 646,405
EPS (basic) n/a
EPS (diluted) n/a
FCF / Share 4.16
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield 10.86%
Payout Ratio n/a
Shares Short 13,729
Short Ratio 0.03
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio 9.21
PS Ratio n/a
PB Ratio 137.57
Revenue n/a
Operating Income -36.63M
Net Income -35.20M
Free Cash Flow 68.00M
Net Cash 638,502
Net Cash / Share 0.01
Gross Margin n/a
Operating Margin n/a
Profit Margin -190.80%
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 4
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(99.48% upside)
Current: $9.95
Target: 19.85
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth389.36%-
Gross Profit18.453.77
Operating Income-33.01-34.41
Net Income-31.57-31.44
Shares Outstanding1.161.16
Earnings Per Share-27.13-27.02
Operating Cash Flow68.057.58
Capital Expenditures-2.14-0.41
Free Cash Flow65.917.17
Cash & Equivalents10339.37
Total Debt3.23-
Net Cash / Debt10039.37
Book Value-41.86-10.41
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Immatics N.V.
Country Germany
Employees 200
CEO Harpreet Singh-Jasuja

Stock Information

Ticker Symbol IMTX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: IMTX


Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct therapeutic modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors; and IMA204, an anti-tumor therapy that targets the malignant tumor cell. Its TCR Bispecifics product candidates include IMA401, a cancer testis antigen for the treatment of solid tumor; and IMA402 for the treatment of solid and hematological malignancies. The company also develops IMA101, a multi-target precision immunotherapy; and IMA301, an off-the-shelf ACT. It has a strategic collaboration agreement with GlaxoSmithKline plc to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications; Amgen Inc.; and MorphoSys to develop novel antibody-based therapies against various cancer antigens that are recognized by T cells. Immatics N.V. is headquartered in Tübingen, Germany.